McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
McKesson (MCK) PT Lowered to $134 at Baird; Remains Sidelined
July 27, 2018 7:15 AM EDTBaird lowered its price target on McKesson (NYSE: MCK) to $134.00 (from $141.00) while maintaining a Neutral rating. MCK claims in-line performance across all three segments. However, YY EBIT facts: U.S. +2% on easy/transitory prior-year comparison, EU -12%, Med-Surg flat, Other -8%. Three of... More
Pharma's middlemen see shares suffer as challenges grow
July 25, 2018 12:04 PM EDTBy Lewis Krauskopf
NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.
Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent.
Six S&P 500 stocks - CVS Health Corp (NYSE:... More
